Robert A. Copeland, President of Research and CSO at Epizyme, Inc. (EPZM), sold 8,371 shares at $22.82 ($191K) on 2015-07-06, disclosed to the SEC on 2015-07-08.
Scheduled sale ($191k) by President of Research and CSO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $22.82 | 4,185 | $96K | 49.9% |
| 2 | $22.90 | 4,186 | $96K | 50.1% |
| Total | $22.86 avg | 8,371 | $191K | 100% |
| Filing → |
| EPZM | SELL | 2017-04-05 | $41K | — | Filing → |
| EPZM | SELL | 2016-08-03 | $83K | — | Filing → |
| EPZM | SELL | 2016-07-07 | $80K | — | Filing → |